Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

The Zepbound approval was on the back of a 469-patient, multi-site, phase II trial, Surmount-OSA, which showed adults taking the therapy averaged up to 20% weight loss. They also had at least 25 ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

It's interesting to note that the SURMOUNT-OSA trial excluded patients with diabetes. In the lead up to its launch to consumers, Eli Lilly's early educational documents that are available to the ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...